BMS-986213
Neoplasms by Site
Bristol-Myers SquibbPhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 89/ 100
Competitive context
928 Active assets in the Neoplasms by Site cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PANITUMUMAB Astellas Pharma Inc | Phase 2 | BBB |
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM Sanofi | Phase 4 | BB |
LIDOCAINE Medical College of Wisconsin | Phase 4 | BB |
DINITROGEN MONOXIDE Medical College of Wisconsin | Phase 4 | BB |
Relatlimab Bristol-Myers Squibb | Phase 2 | BB |
View all 50 →
Same molecule, other indications
BMS-986213 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →